Seminars
Identify Promising Novel Leads: Axcelead’s integrated HTS platform powered by computational chemistry and AI/ML
"*" indicates required fields
Webinar Overview :
High Throughput Screening (HTS) is one of the most powerful tools in small molecule drug discovery for identifying promising novel leads. The success of HTS depends on the design of an appropriate screening flow, the development of robust assay systems, and the availability of a high-quality compound library.
Axcelead, a drug discovery solution provider, established in 2017 as a spin-off from Takeda Pharmaceutical Company, inherited Takeda’s preclinical research functions, including HTS. With a proprietary library of over 1.2 million compounds, 60% of which are originally synthesized, Axcelead excels in identifying high-quality hits.
In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies.
Speaker
Akito Hata
Screening Business Unit Head / Digital Unit Head, Axcelead Drug Discovery Partners, Inc.
- A scientist in early stage drug discovery particularly in in vitro biology and high-throughput screening
- Joined Axcelead Drug Discovery Partners, Inc. in 2021 and contributed to the development of kinase inhibitor platform and targeted protein degradation platform
- Led Protein Science team since 2023 and took on responsibility of Screening Business Unit since January 2024
- Previously worked as a research scientist at Takeda Pharmaceuticals, Inc. both in Japan and Boston, US. Experienced a wide variety of early stage small molecule drug discovery projects at Takeda Japan, and biologics projects for antibody and cell therapy at Takeda Boston
Host
Masayuki Ii, PhD
CSO, Axcelead Drug Discovery Partners, Inc.
- Former Head of inflammation DDU, Takeda Pharmaceutical Company
- >29 years of experience in Drug discovery, lead of research in global development programs
- >20 publications, >40 patents